Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to sell.

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 5.89%, which has investors questioning if this is right time to ...

Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Sangamo Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.61, indicating that its share price is 61% ...

Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets ...

RICHMOND, Calif., April 03, 2025--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM RICHMOND, Calif., ...

Investing.com -- Shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) surged 30.2% following the announcement of a significant licensing agreement with pharmaceutical giant Eli Lilly and Company (NYSE ...

Sangamo said in November 2024 that the company only had enough money in the bank to last until the first quarter of 2025. It's not immediately clear how far Lilly’s $18 million cash payment will ...